Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells

T Terakawa¹, H Miyake*, J Furukawa¹, SL Ettinger², ME Gleave² and M Fujisawa¹

¹Division of Urology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; ²The Prostate Centre, Department of Surgery, Vancouver General Hospital, Vancouver, Canada

BACKGROUND: The objective of this study was to investigate the effects of interleukin-6 (IL-6) overexpression in androgen-dependent prostate cancer LNCaP cells on their phenotype under an androgen-deprived condition.

METHODS: We established IL-6-overexpressing LNCaP (LNCaP/IL-6) by introducing the expression vector containing IL-6 cDNA. Changes in the phenotype in LNCaP/IL-6 were compared with that in LNCaP transfected with control vector alone (LNCaP/Co).

RESULTS: In vitro, the growth of LNCaP/IL-6 was significantly inferior to that of LNCaP/Co under an androgen-deprived condition. Similarly, LNCaP/IL-6 tumour in nude mice rapidly regressed after castration; however, LNCaP/Co tumour growth was transiently inhibited after castration and then continuously accelerated. After androgen withdrawal, expression levels of phosphorylated p44/42 mitogen-activated protein kinase (MAPK) and Akt in LNCaP/IL-6 were markedly upregulated compared with those in LNCaP/Co; however, additional treatment with specific inhibitor of the MAPK or Akt signalling pathway significantly inhibited the growth of LNCaP/IL-6 compared with that of LNCaP/Co. Furthermore, gene microarray analyses showed that androgen deprivation resulted in differential expression of genes involved in growth, apoptosis and tumorigenesis between LNCaP/Co and LNCaP/IL-6.

CONCLUSION: Excessive secretion of IL-6 by LNCaP cells in an autocrine manner may have a suppressive function in their growth and acquisition of androgen-independent phenotype under an androgen-deprived condition.

Keywords: prostate cancer; interleukin-6; androgen-independent progression; androgen withdrawal; signal transduction

The prognosis of patients with organ-confined prostate cancer has been remarkably improved with technical advances in surgical as well as radiological treatments; however, androgen withdrawal therapy remains the only effective form of systemic therapy for men with advanced prostate cancer. Initially, >80% of such patients respond favourably to this therapy; however, progression to the lethal and untreatable stage of androgen independence ultimately occurs within a few years in the majority of these patients (Rosenberg and Small, 2003). Recently completed phase III trials first demonstrated a survival benefit of docetaxel-based combined regimen in patients with hormone-refractory disease, but these improved effects were not substantial (Petrylak et al., 2004; Tannock et al., 2004). Collectively, these findings suggest that androgen-independent (AI) progression remains the major obstacle to effective control and cure of advanced disease, emphasising the need for a novel therapeutic strategy that targets the molecular mechanism mediating emergence of the AI phenotype.

Despite intensive efforts in the field of prostate cancer research, the precise molecular mechanism of progression to androgen independence has not been fully elucidated; however, several hypotheses explaining the complex process during AI progression have been reported (Arnold and Isaacs, 2002; So et al., 2005; Kasper and Cookson, 2006). One potentially important mechanism is the maintenance of androgen receptor (AR) signalling in hormone-refractory prostate cancer by crosstalk between AR and nonsteroidal molecules, including cytokines and growth factors (Culig et al., 1994; Craft et al., 1999; Culig, 2004; Wang et al., 2008). Of these, interleukin-6 (IL-6), a pleiotropic cytokine involved in the regulation of hematopoiesis, immune response, inflammation, bone metabolism and neural development (Kishimoto et al., 1992), has been regarded as one of the most important mediators during AI progression of prostate cancer through the ligand-independent activation of AR (Okamoto et al., 1997; Hobisch et al., 1998; Lou et al., 2000; Lin et al., 2001; Ueda et al., 2002a, b; Lee et al., 2003).

The biological activities of IL-6 are mediated by the IL-6 receptor; that is, the binding of IL-6 to its receptor results in the activation of intracellular signalling, including mitogen-activated protein kinase (MAPK), phosphoinositid 3′-kinase (PI3K)/Akt and Janus-activated kinase (JAK)/signal transducers and activation of transcription (STAT) pathways (Kishimoto et al., 1992; Corcoran and Costello, 2003). In recent studies, it was also demonstrated that modulations of three major downstream signalling pathways, MAPK, Akt and STAT3, are involved in AI transactivation of AR.
by IL-6 (Yang et al., 2003). However, the reported actions of IL-6 in conferring malignant phenotype to prostate cancer cells remain controversial, with some studies showing positive findings (Okamoto et al., 1997; Hobisch et al., 1998; Lou et al., 2000; Lin et al., 2001; Ueda et al., 2002a,b; Lee et al., 2003), and others showing negative findings (Mori et al., 1999; Deeble et al., 2001; Hobisch et al., 2001; Jia et al., 2004; Lee et al., 2007). It also remains controversial whether signal transduction pathway is most dominantly associated with the transactivation of AR induced by IL-6 (Chen et al., 2000; Chung et al., 2000; Corcoran and Costello, 2003; Yang et al., 2003). For example, Chen et al. (2000) reported that inhibition of STAT3 rather than MAPK results in inhibition of AR-mediated gene activation in response to IL-6, whereas Yang et al. (2003) showed that IL-6 can enhance AR transactivation through both the STAT3 and MAPK pathways, but not the PI3K-Akt pathway. Furthermore, few studies have investigated the crosstalk between AR and IL-6 secreted in an autocrine manner in prostate cancer cells (Lee et al., 2003, 2004).

In this study, therefore, we evaluated the effects of IL-6 overexpression in human androgen-dependent (AD) prostate cancer LNCaP cells on changes in their phenotype before and after androgen withdrawal to assess the functional role of IL-6 secreted in an autocrine manner as a ligand-independent activator of AR.

MATERIALS AND METHODS

Tumour cell lines

LNCaP and PC3, derived from human prostate cancer, were purchased from the American Type Culture Collection (Rockville, MD, USA). Cells were maintained in RPMI (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated fetal bovine serum. To investigate the androgen deprivation effect, steroid hormone-depleted charcoal-stripped medium (CSM) was prepared as described earlier (Saeed et al., 1997).

Expression plasmid and transfection to tumour cells

The cDNA fragment encoding human IL-6 was directly cloned into the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The pcDNA3.1/IL-6 construction was transfected into LNCaP cells by the liposome-mediated gene transfer method (Miyake et al., 2000a). Briefly, 2 x 10⁵ LNCaP cells were plated in a 6-cm dish, 1 day before transfection. A measure of 5 μg of purified pcDNA3.1/IL-6 or pcDNA3.1 (as a control) was added to LNCaP cells after preincubation for 30 min with 5 μg of lipofectamine reagent and 3 ml of serum-free OPTI-MEM (Life Technologies). Drug selection in 300 μg/ml Geneticin (Life Technologies) was begun 3 days after transfection. Three weeks after the drug selection, colonies were harvested with cloning cylinders and expanded to cell lines.

Enzyme-linked immunosorbent assay

The concentrations of IL-6 in overnight culture supernatants of 5 x 10⁶ LNCaP sublines were measured using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kit for human IL-6 according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). Similarly, a sandwich ELISA kit for human prostate-specific antigen (PSA) (Zymed Laboratories, South San Francisco, CA, USA) was used to determine the concentrations of PSA in overnight culture supernatants of 5 x 10⁶ LNCaP sublines and those in sera from nude mice bearing the subcutaneous tumours of LNCaP sublines.

Cell proliferation assay

To compare the in vitro proliferation of LNCaP sublines, 5 x 10⁵ cells of each cell line were seeded in each well of 12-well plates, and the number of cells in each cell line was counted daily by triplicate. In addition, the effect of androgen deprivation on the proliferation of LNCaP sublines with and without additional treatment with IL-6 (Sigma-Aldrich, Tokyo, Japan), UO126 (SA Bioscience, Frederick, MD, USA) or LY294002 (SA Bioscience) was also examined; that is, following the culture of LNCaP sublines in the standard medium for 3 days, the medium was replaced with CSM with and without supplementary IL-6, UO126 or LY294002, and the number of cells was counted.

Western blot analysis

Western analysis was performed as described earlier (Miyake et al., 2000a). Briefly, samples containing equal amounts of protein (25 μg) from lysates of the LNCaP sublines cultured in either standard medium or CSM were electrophoresed on an SDS–polyacrylamide gel and transferred to a nitrocellulose filter. The filters were blocked in PBS containing 5% nonfat milk powder at 4 °C overnight and then incubated for 1 h with antibodies against IL-6 receptor (R&D Systems), AR, β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and total and phosphorylated STAT3, p44/42 MAPK and Akt (Cell Signaling Technology, Danvers, MA, USA). The filters were then incubated for 30 min with horseradish peroxidase-conjugated secondary antibodies (Amersham Pharmacia Biotech, Arlington Heights, IL, USA), and specific proteins were detected using an enhanced chemiluminescence western blotting analysis system (Amersham Pharmacia Biotech).

Gene microarray

Gene microarrays of 34 580 (70-mer) human oligos representing 24 650 genes and 37 123 gene transcripts printed on aminosilane-coated microarray slides were supplied by the microarray facility of the Prostate Centre at Vancouver General Hospital (Vancouver, Canada), and microarray analysis was performed as described earlier (Snoek et al., 2009). Briefly, microarrays were hybridized with 10 μg of total RNA from independently prepared triplicate samples of LNCaP sublines before and after androgen deprivation, labelled with CY5 against 10 μg of Universal Human Reference RNA labelled with CY3 (Stratagene, La Jolla, CA, USA), and assessed using the 3DNA Array 350 Expression Array Detection kit according to the manufacturer’s instructions (Genisphere, Hatfield, PA, USA). After overnight hybridization and washing, arrays were scanned on a Scan Array Express Microarray Scanner (Perkin-Elmer, Waltham, MA, USA), and signal quality and quantity were determined using the ImaGene 8.0 software (BioDiscovery, El Segundo, CA, USA). Comparative analysis of the gene expression profiles in each cell line was conducted to identify genes that are differentially regulated by overexpression of IL-6. Genes were considered to be significantly different if the mean expression level in the IL-6-overexpressing cells was at least 2.0-fold greater or 2.0-fold less than that seen in the control cells.

Assessment of in vivo tumour growth

Male athymic nude mice (BALB/c-nu/nu males, 6–8 weeks old) were purchased from Clea Japan (Tokyo, Japan) and housed in a controlled environment at 22°C on a 12-h light, 12-h dark cycle. Animals were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Each experimental group consisted of 20 mice. The tumour cells of each cell line were trypanospun, washed twice with PBS, and 5 x 10⁵ cells were subcutaneously injected with 100 μl of Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA) into right
flank of mice. The subcutaneous tumour growth was measured once per week using calipers as described earlier (Miyake et al., 1996); that is, the longest surface length (a) and width perpendicular to this length (b) were measured, and tumour size was reported as a x b. Furthermore, when the tumour size was >80 mm², 10 of the 20 mice were castrated, and the growth of subcutaneous tumour was continuously measured to estimate the effect of androgen withdrawal on in vivo growth of the LNCaP subline.

Statistical analysis

Differences between the two groups were compared using the unpaired t-test. All statistical calculations were performed using Statview 5.0 software (Abacus Concepts, Inc., Berkley, CA, USA), and P-values < 0.05 were considered significant.

RESULTS

IL-6 production in LNCaP sublines

LNCaP was transfected with pcDNA3.1/IL-6 or pcDNA3.1 alone as a control. After drug selection, several Geneticin-resistant stable transfectants were randomly isolated. The culture supernatants of LNCaP sublines and PC3 were analysed by sandwich ELISA to measure the IL-6 concentrations. All of the IL-6-transfected LNCaP (LNCaP/IL-6#1 to LNCaP/IL-6#4) secreted abundant immunoreactive IL-6 protein in amounts equal to those of PC3 originally expressing the IL-6 gene (Okamoto et al., 1997); however, limited IL-6 was detected in the supernatants of the parental LNCaP (LNCaP/P) and the cell line transfected with control vector-only transfected cell line (LNCaP/Co) (Figure 1). Furthermore, there was no significant difference in the expression level of IL-6 receptor among these LNCaP sublines (data not shown).

In the following in vitro experiments, almost identical findings were obtained from IL-6-transfected cell lines (LNCaP/IL-6#1 to LNCaP/IL-6#4) or their control cell lines (LNCaP/P and LNCaP/Co); therefore, we subsequently presented the data for LNCaP/IL-6#1 and LNCaP/Co only.

In vitro growth of LNCaP sublines

To examine the effects of IL-6 overexpression on in vitro growth of LNCaP under conditions with and without androgen, the growth of LNCaP sublines cultured in the standard medium and that in CSM were assessed. As shown in Figure 2, there was no significant difference in the growth of LNCaP sublines cultured in the standard medium; however, after androgen deprivation by replacing the standard medium with CSM, the growth of LNCaP/IL-6#1 was significantly inhibited compared with that of LNCaP/Co.

In vivo growth of LNCaP sublines

To examine the in vivo effect of IL-6 overexpression on tumour growth, 5 x 10⁶ cells of each cell line were injected subcutaneously into 20 nude mice; then 10 of the 20 mice were castrated when the tumour size reached 80 mm² or greater. In intact mice without castration, the growth of LNCaP/IL-6#1 tumour was significantly faster than that of LNCaP/Co tumour (Figure 2C). However, LNCaP/IL-6#1 tumour in nude mice rapidly regressed after castration, whereas LNCaP/Co tumour growth was transiently inhibited after castration and then continuously accelerated without regulation of androgen (Figure 2D).

PSA production by LNCaP sublines

As shown in Figure 3A, when maintained in standard medium, PSA concentration in the culture supernatant of LNCaP/IL-6#1 was significantly lower than that of LNCaP/Co; however, under the androgen-deprived condition, PSA concentrations of both LNCaP/Co and LNCaP/IL-6#1 drastically decreased, and there was no significant difference in PSA concentration between these two cell lines. Inconsistent with the in vitro finding, serum concentration of PSA, which was adjusted based on tumour volume, in intact mice bearing LNCaP/IL-6#1 tumour before castration was significantly lower than that in mice bearing LNCaP/Co tumour. Two months after castration, PSA concentration in mice bearing LNCaP/IL-6#1 tumour was significantly reduced compared with that before castration, whereas PSA concentration in mice bearing LNCaP/Co tumour acquiring the AI phenotype became greater than that before castration (Figure 3B).

Effects of exogenous IL-6 treatment on signal transduction pathways in LNCaP sublines

To evaluate whether treatment with exogenous IL-6 differentially influences its major downstream signalling pathways, western blot analyses of both phosphorylated and total MAPK, Akt and STAT3 expression in LNCaP sublines were performed. Despite the lack of a significant difference in the expression levels of phosphorylated Akt between LNCaP/Co and LNCaP/IL-6#1 (data not shown), exogenous IL-6 rapidly activated MAPK and STAT3 pathways in LNCaP/Co, but not in LNCaP/IL-6#1; that is, phosphorylated p44/42 MAPK and STAT3, which were not induced in LNCaP/IL-6#1, became detectable in LNCaP/Co 5 and 15 min after treatment with IL-6, respectively (Figure 4).

Effects of androgen withdrawal on signal transduction pathways in LNCaP sublines

To determine whether androgen withdrawal modulates the activation patterns of signal transduction pathways through AR, changes in expression of both phosphorylated and total MAPK, Akt and STAT3 in LNCaP sublines were evaluated. There were no significant differences in the expression levels of both phosphorylated and total STAT3 between LNCaP/Co and LNCaP/IL-6#1 under an androgen-deprived condition (data not shown). As shown in Figure 5A, however, androgen withdrawal induced remarkable activation of MAPK and Akt pathways in LNCaP/IL-6#1 compared with that in LNCaP/Co; that is, expression levels of both phosphorylated Akt and p44/42 MAPK in LNCaP/IL-6#1 were
significantly upregulated 4 days after androgen withdrawal, whereas there was no upregulation of both phosphorylated Akt and p44/42 MAPK in LNCaP/Co until 6 days after the initiation of culture under an androgen-deprived condition.

Consistent with the evaluation of changes in the downstream signalling pathways of IL-6, we investigated the effect of additional treatment with UO126 or LY294002, a selective inhibitor of mitogen-activated protein kinase kinase (MEK) or PI3K on the growth of LNCaP sublines cultured in the androgen-deprived condition. Treatment with UO126 or LY294002 inhibited the growth of LNCaP/Co and LNCaP/IL-6#1 under androgen-deprived condition was evaluated by counting in triplicate the number of cells in each cell line daily. Bars, s.d. ** and *, differ from LNCaP/Co (P < 0.01 and P < 0.05, respectively). (C) Intact nude mice were subcutaneously given 5 × 10⁶ cells of LNCaP sublines in the right flank on day 0. Tumour size was expressed as the product of the maximal diameter multiplied by the perpendicular diameter. Bars, s.d. of tumour size; 10 mice per group. ** and *, differ from LNCaP/Co (P < 0.01 and P < 0.05, respectively). (D) Following subcutaneous injection of LNCaP sublines, nude mice were castrated on day 0 when the tumour size reached 80 mm² or greater. Tumour size in castrated mice was then serially measured as described above. Bars, s.d. of tumour size; 10 mice per group. ** and *, differ from LNCaP/Co (P < 0.01 and P < 0.05, respectively).

Figure 2 Effect of interleukin-6 (IL-6) overexpression on in vitro and in vivo cell growth of LNCaP sublines before and after androgen ablation. (A) In vitro proliferation of LNCaP/Co (control vector-only transfected cell line) and LNCaP/IL-6#1 (IL-6-transfected cell line) cultured in the standard medium was evaluated by counting in triplicate the number of cells in each cell line daily. Bars, s.d. (B) Following culture in standard medium for 3 days, the medium was replaced with steroid hormone-depleted charcoal-stripped medium, and in vitro proliferation of LNCaP/Co and LNCaP/IL-6#1 under androgen-deprived condition was evaluated by counting in triplicate the number of cells in each cell line daily. Bars, s.d. ** and *, differ from LNCaP/Co (P < 0.01 and P < 0.05, respectively).

Changes in the expression of AR in LNCaP sublines were then analysed. As shown in Figure 5C, expression levels of AR in both LNCaP/Co and LNCaP/IL-6#1 were markedly inhibited 4 days after androgen withdrawal; however, AR expression in LNCaP/Co was restored to the basal level 6 days after androgen withdrawal, despite the continuous suppression of AR expression in LNCaP/IL-6 until 6 days after the initiation of culture without androgen.

Gene microarray analysis in LNCaP sublines

To further address the molecular mechanism involved in the enhanced sensitivity of androgen withdrawal in LNCaP/IL-6#1, the influence of IL-6 overexpression on global gene expression was assessed by gene microarray analysis. We analysed the gene expression profiles in LNCaP/Co and LNCaP/IL-6#1 cultured in both the standard medium and CSM. Excluding genes differentially expressed between LNCaP/Co and LNCaP/IL-6#1 cultured in the standard medium, a total of 223 genes were found to be differentially expressed in LNCaP/IL-6#1 at least 2.0-fold greater or 2.0-fold less than those of LNCaP/Co under an androgen-deprived condition. On the basis of the biological relevance and magnitude of changes, 40 of these 223 genes were selected, and presented in Table 1. For example, MAP3K7 was up-regulated in
LNCaP/IL-6#1 compared with that in LNCaP/Co, which is consistent with the findings suggesting the activation of MAPK pathway in LNCaP/IL-6#1, and this might be due to an adaptive change to resist to proapoptotic stimuli induced by androgen ablation. In addition, expression levels of some genes associated with the progression of prostate cancer, such as relaxin, vascular endothelial growth factor (VEGF), vimentin and bone morphogenetic protein-6 (BMP-6) (Soker et al, 2001; Dai et al, 2005; Thompson et al, 2006; Feng et al, 2007; Wei et al, 2008), were significantly downregulated in LNCaP/IL-6#1 compared with LNCaP/Co. Overall, there are several genes listed in Table 1, which are known to have functions mediating cell growth, apoptosis, and tumorigenesis, showing expression profiles that are reasonable for theoretically elucidating the molecular mechanism mediating enhanced sensitivity to androgen withdrawal by overexpression of IL-6.

**DISCUSSION**

Since reports showing elevated levels of circulating IL-6 in men with advanced prostate cancer (Twillie et al, 1995; Drachenberg et al, 1999), a number of studies have been performed to clarify how IL-6 signalling is involved in the progression of prostate cancer. Consequently, it has been suggested that crosstalk between AR and IL-6 may have an important function in the activation of AR signalling in a ligand-independent manner (Okamoto et al, 1997; Hobisch et al, 1998; Lou et al, 2000; Lin et al, 2001; Ueda et al, 2002a,b; Lee et al, 2003). To date, however, it remains controversial whether IL-6 confers a malignant phenotype on prostate cancer cells, particularly under an androgen-deprived condition (Okamoto et al, 1997; Hobisch et al, 1998, 2001; Mori et al, 1999; Lou et al, 2000; Deeble et al, 2001; Lin et al, 2001; Ueda et al, 2002a,b; Lee et al, 2003, 2007; Jia et al, 2004). Accordingly, in this study, we established the IL-6-overexpressing LNCaP cells (i.e., LNCaP/IL-6#1), and assessed the effects of IL-6 secreted through an autocrine manner on their phenotype before and after androgen withdrawal.

The growth patterns of LNCaP sublines both in vitro and in vivo were initially compared. Before androgen ablation, despite the lack of a significant difference in the in vitro growth between LNCaP sublines, LNCaP/IL-6#1 tumour grew significantly faster than LNCaP/Co tumour. Under an androgen-deprived condition, however, the in vitro growth of LNCaP/IL-6#1 was significantly suppressed compared with that of LNCaP/Co. This enhanced sensitivity of LNCaP/IL-6#1 to androgen withdrawal was more remarkable in vivo; that is, after castration, LNCaP/IL-6#1 tumour rapidly regressed and completely disappeared. According to the previously reported studies, the effects of IL-6 on the growth of LNCaP cells seem to be puzzling with some groups showing growth stimulation, whereas others showing growth inhibition (Spiotto and Chung, 2000; Lee et al, 2003, 2007; Jia et al, 2004). For example, Lee et al (2007) reported the bifunctional action of IL-6 according to the manner of its secretion; that is, IL-6 acts as a growth inhibitor for LNCaP cells by a paracrine mechanism, whereas endogenously produced IL-6 stimulates LNCaP cell growth by an autocrine mechanism. As most of the previously observed effects of IL-6 on the growth of prostate cancer cells were examined in vitro, this study is the first to demonstrate the following evidence that overexpression of IL-6 in LNCaP cells enhanced their sensitivity to androgen withdrawal both in vitro and in vivo, resulting in marked growth inhibition immediately after androgen ablation. Furthermore, it would be of interest to investigate the effects of an antiandrogen, such as bicalutamide, on the growth of LNCaP sublines.
PSA is a reliable tumour marker showing a proportional change in relation to the degree of prostate cancer progression (Lilja et al., 2008). In this study, PSA concentrations in culture supernatants and sera from mice generally reflected the proliferative status of LNCaP sublines cultured in vitro and that subcutaneously implanted, respectively, under both conditions with and without androgen. Interestingly, the amount of baseline PSA production by LNCaP/IL-6#1 was significantly smaller than that by LNCaP/Co both in vitro and in vivo, when androgen was supplemented; however, several earlier studies have shown that treatment of LNCaP cells with IL-6 enhances their AR-mediated PSA gene expression through an increase in PSA reporter activity (Lin et al., 2001; Ueda et al., 2002a; Lee et al., 2003). Although the discrepancy described above cannot be clearly explained, it would be speculated that overexpression of IL-6 by LNCaP cells itself rather than exogenous administration of IL-6 may render them undifferentiated, resulting in a lesser amount of PSA production than that in LNCaP/Co cells.

Considering the unique proliferative potential and PSA production of LNCaP/IL-6#1 cells, it would be of interest to investigate whether LNCaP/IL-6#1 exhibits a different response to exogenous IL-6 compared with that of LNCaP/Co. As reported earlier (Ueda et al., 2002a; Jia et al., 2004), exogenous IL-6 induced rapid activation of MAPK and STAT3 pathways in LNCaP/Co cells, which are unable to secrete endogenous IL-6. In addition, rapid activation of MAPK pathway by IL-6 was also observed in a subline of LNCaP derived by chronic treatment with IL-6 (Steiner et al., 2003). However, treatment of LNCaP/IL-6#1 with exogenous IL-6, which was a markedly greater amount than that produced by LNCaP/IL-6#1, failed to activate the MAPK and STAT3 pathways. Collectively, these findings strongly suggest that IL-6 may exert various effects on changes in the phenotype of prostate cancer cells through different molecular mechanisms according to the manner of secretion.

Another point of interest is the mechanism whereby overexpression of IL-6 enhances sensitivity of LNCaP cells to androgen withdrawal. To address this point, it was investigated whether the downstream signalling pathways of IL-6 are differentially regulated by androgen between LNCaP sublines. Although the growth of LNCaP/IL-6#1 was significantly inhibited compared with that of LNCaP/Co under an androgen-deprived condition, Akt and MAPK pathways in LNCaP/IL-6#1, which are generally regarded as a positive regulator of prostate cancer cell growth through the transactivation of AR (Ueda et al., 2002b; Corcoran and Costello, 2003; Lee et al., 2003), appeared to be markedly activated following androgen withdrawal compared with those in LNCaP/Co. However, stress-induced increase in several antiapoptotic genes, such as bcl-2, clusterin, insulin-like growth factor binding protein-2 (IGFBP-2), IGFBP-5 and heat-shock protein 27, have been shown to have important functions in the AI progression of prostate cancer after castration (Gleave et al., 1999; Miyake et al., 2000b; Kiyama et al., 2003; Rocchi et al., 2004). Therefore, these findings suggest that activation of Akt and MAPK pathways after a proapoptotic trigger in LNCaP/IL-6#1 represents an adaptive mechanism mediating cell survival. In addition, this hypothesis was supported by the finding that additional treatment with U0126 or LY294002, a selective inhibitor of MEK or PI3K, respectively, after androgen deprivation resulted in significant growth inhibition of LNCaP/IL-6#1 compared with that of LNCaP/Co. Furthermore, the restoration of AR expression after androgen withdrawal in LNCaP/IL-6#1 was shown to be significantly delayed compared with that in LNCaP/Co; however, the unique proliferative potential and PSA production of LNCaP/IL-6#1 could not be entirely explained by the changes in AR expression in this cell line.

We further investigated the molecular mechanism underlying the enhancement of androgen withdrawal-induced apoptotic cell death of LNCaP/IL-6#1 using gene microarray analysis. Gene expression profiling showed that 223 genes were differentially expressed between LNCaP/Co and LNCaP/IL-6#1 under androgen-deprived condition, and 40 of these 223 were listed considering the expression differences in some genes in LNCaP/Co before and after androgen withdrawal were consistent with those in parental LNCaP reported in earlier studies (Stewart et al., 2001; Thompson et al., 2006), suggesting the reliability of our gene microarray analysis. Although
it would be necessary to perform functional analysis to identify genes having potential functions in the mechanism described above, several candidate genes could be identified by gene microarray analysis. For example, androgen withdrawal-induced marked downregulation of relaxin, VEGF, vimentin and BMP-6, involved in cancer progression (Soker et al, 2001; Dai et al, 2005; Thompson et al, 2006; Feng et al, 2007; Wei et al, 2008) as well as upregulation of cellular retinol binding protein 7 and interferon-γ receptor, negatively regulating cancer progression (Kuppumbatti et al, 2001; Yang et al, 2008), in LNCaP/IL-6#1. In conclusion, this is the first study to show enhanced sensitivity to androgen withdrawal due to overexpression of IL-6 in AD human prostate cancer LNCaP cells. Furthermore, the present findings suggest that the difference in response to exogenous IL-6 between LNCaP/Co and LNCaP/IL-6#1 may, at least in part, be involved in the differential sensitivity to androgen withdrawal between these two sublines, and that despite the significant activation of Akt and MAPK pathways in LNCaP/IL-6#1 compared with that in LNCaP/Co under an androgen-deprived condition, this might be due to the response to proapototic stimuli representing an adaptive cell survival mechanism. Although gene microarray analysis identified several potentially important candidate genes responsible for the different sensitivities to androgen ablation between LNCaP/Co and LNCaP/IL-6#1 by globally evaluating their gene expression profiles, it would be further required to accumulate the intensive investigation to elucidate the molecular mechanism underlying changes in the phenotype of LNCaP cells by overexpression of IL-6.

**REFERENCES**

Arnold JT, Isaacs JT (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault. *Endocr Relat Cancer* 9: 61 – 73

Cajo GC, Horne BE, Kelley WL, Schwager F, Georgopoulos C, Genevau P (2006) The role of the DIF motif of the DnaJ (Hsp40) co-chaperone in the regulation of the DnaK (Hsp70) chaperone cycle. *J Biol Chem* 281: 12436 – 12444

© 2009 Cancer Research UK

British Journal of Cancer (2009) 101(10), 1731 – 1739

**Table 1** Gene microarray analysis in LNCAP sublines under androgen-deprived condition

| Gene symbol | Genebank accession no. | Gene name | Fold difference a |
|-------------|------------------------|-----------|-------------------|
| KCNJ3       | BC022495               | Potassium inwardly rectifying channel, subfamily J, member 3 | 23.40 |
| CB1R        | BC035789               | Cerebellin 2 precursor | 21.69 |
| DNAJC15     | BC019010               | DnaJ (Hsp40) homolog, subfamily C, member 15 | 16.99 |
| KHDC1       | BC022080               | KH homology domain containing I | 9.21 |
| GRIK2       | BC063814               | Glutamate receptor, ionotropic, kainate 2 | 8.97 |
| CDH18       | BC031051               | Cadherin 18, type 2 | 8.28 |
| GABRG2      | BC069348               | Gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 8.16 |
| AMOTL1      | BC037539               | Angiomotin like 1 | 3.79 |
| INFNG2      | BC003624               | Interferon gamma receptor 2 (interferon gamma transducer 1) | 3.09 |
| HOXC12      | AH010514               | Homeobox C12 | 2.95 |
| ARHGEF1I    | BC057394               | Rho guanine nucleotide exchange factor (GEF) I | 2.73 |
| USP51       | BC039507               | Ubiquitin specific peptidase 51 | 2.63 |
| ABCC4       | BC041560               | ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | 2.51 |
| SATBZ       | BC098136               | SATB homeobox 2 | 2.48 |
| NAPPT       | BC072439               | Nicotinamide phosphoribosyltransferase | 2.42 |
| DYNC1I1     | BC064521               | Dynein, cytoplasmic 1, intermediate chain 1 | 2.34 |
| FBLN7       | BC035785               | Fibulin 7 | 2.25 |
| RB7P        | BC063013               | Retinol binding protein 7, cellular | 2.21 |
| CIQL1       | BC008798               | Complement component 1, q subcomponent-like 1 | 2.13 |
| MAP3K7      | BC017715               | Mitogen-activated protein kinase kinase kinase 7 | 2.05 |
| VEGFA       | BC065522               | Vascular endothelial growth factor A | 2.10 |
| HIST1H2BO   | BC016720               | Histone cluster 1, H2bo | 2.29 |
| HIST1H2BH   | BC096116               | Histone cluster 1, H2bh | 2.31 |
| GPRC5C      | BC110848               | G protein-coupled receptor, family C, group 5, member C | 2.33 |
| BMP6        | BC112352               | Bone morphogenetic protein 6 | 3.01 |
| SH3GL3      | BC042864               | SH3-domain GRB2-like 3 | 3.07 |
| RGS16       | AF09356                | Regulator of G-protein signaling 16 | 3.99 |
| HRK         | NM003806               | Harakiri, BCL2 interacting protein (contains only BH3 domain) | 4.05 |
| TCF4        | BC152084               | Transcription factor 4 | 4.40 |
| EP58        | BC030010               | Epidermal growth factor receptor pathway substrate 8 | 5.32 |
| PPP1R1A     | BC022470               | Protein phosphatase 1, regulatory (inhibitor) subunit 1A | 8.08 |
| HOXA13      | BC077571               | Homeobox A13 | 8.28 |
| MAF         | BC081542               | v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) | 9.39 |
| PTTRB       | BC051329               | Protein tyrosine phosphatase, receptor type, B | 9.55 |
| RLN1        | BC005956               | Relaxin 1 | 11.33 |
| VIM         | M14144                 | Vimentin | 18.81 |
| ACO1       | BC039261               | Acyl-CoA synthetase short-chain family member | 28.42 |
| S100A10     | BC105786               | S100 calcium binding protein A10 | 37.45 |
| ROS2        | BC042755               | Regulator of G-protein signaling 2, 24 kDa | 89.77 |

aThe average magnitude of difference in each gene expression in LNCaP/IL-6#1 relative to that in LNCaP/Co.
Chen T, Wang LH, Farrar WL (2000) Interleukin-6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60: 2132–2135

Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM (2000) Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 42: 1–7

Corcoran NM, Costello AJ (2003) Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 91: 545 – 553

Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280 – 285

Culig Z (2004) Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22: 179 – 184

Culig Z, Hobisch A, Cronauer MV, Radmayer C, Trampan J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474 – 5478

Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET (2005) Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65: 8274 – 8285

Deebre PD, Murphy DJ, Parsons SJ, Cox ME (2001) Interleukin-6- and cycler AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21: 8471 – 8882

Drachenberg DE, Elgammal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127 – 133

Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Li R, Ayala G, Ittmann MM, Agoulnik AI (2007) Relaxin promotes prostate cancer progression. Clin Cancer Res 13: 1695 – 1702

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Berald E, Goldie J (1999) Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5: 2891 – 2898

Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z (2001) Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6)-treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7: 2941 – 2948

Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA (2004) Androgen receptor signaling: mechanism of interleukin-6 inhibition. Cancer Res 64: 2619 – 2626

Kasper S, Cookson MS (2006) Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33: 201 – 210

Kishimoto T, Akira S, Taga T (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Science 258: 593 – 597

Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63: 3575 – 3584

Kuppumbatti YS, Rexer B, Nakajo S, Nakaya K, Mira-y-Lopez R (2001) CRBP suppresses breast cancer cell survival and anchorage-independent growth. Oncogene 20: 7413 – 7419

Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239 – 442

Miyake H, Hara I, Yoshimura K, Eto H, Arakawa S, Wada S, Chihara K, Kamidono S (1996) Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res 56: 2440 – 2445

Miyake H, Nelson C, Rennie PS, Gleave ME (2000a) Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3’-kinase pathway. Endocrinology 141: 2257 – 2265

Miyake H, Nelson C, Rennie PS, Gleave ME (2000b) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170 – 176

Miyake H, Pollak M, Gleave ME (2000c) Castration-induced up-regulation of insulin-like growth factor binding protein-3 potentiates insulin-like growth factor-1 activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60: 3058 – 3064

Mori S, Murakami-Mori K, Bonavida B (1999) Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257: 609 – 614

Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141 – 146

Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513 – 1520

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M (2004) Heat shock protein 27 increases 21 decreases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595 – 6602

Rosenberg J, Small EJ (2003) Prostate cancer update. Curr Opin Oncol 15: 217 – 221

Saeed B, Zhang H, Ng SC (1997) Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media. Prostate 31: 145 – 152

Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME, Rennie PS (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39 – 47

So A, Gleave M, Hurtado-Col A, Nelson C (2005) Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1 – 7

Solomon KA, Kaefler M, Johnson M, Klagsbrun M, Atala A, Freeman MR (2001) Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159: 651 – 659

Spiotto MT, Chung TD (2000) STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88 – 98

Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z (2003) Accelerated growth inhibition in vivo of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162: 655 – 663

Stewart RJJ, Panigrahy D, Flynn E, Folkman J (2001) Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688 – 693

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Therasse P, James RD, Petrini JS, Gleave ME, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502 – 1512

Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC (2006) Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate 66: 1698 – 1709
Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. *Urology* 45: 542–549

Ueda T, Bruchovsky N, Sadar MD (2002a) Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. *J Biol Chem* 277: 7076–7085

Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002b) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. *J Biol Chem* 277: 38087–38094

Wang G, Wang J, Sadar MD (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. *Cancer Res* 68: 9918–9927

Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P, Zhu T, Song A, Zhao L, Han Z, Chen G, Wang S, Meng L, Zhou J, Lu Y, Wang S, Ma D (2008) Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. *Anticancer Res* 28: 327–334

Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SL, Liu K (2008) Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. *Int J Cancer* 122: 350–362

Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C (2003) Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. *Biochem Biophys Res Commun* 305: 462–469

Effects of interleukin-6 secretion on prostate cancer

T Terakawa et al

© 2009 Cancer Research UK

British Journal of Cancer (2009) 101(10), 1731 – 1739